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Monitoring and management of hypertension  
with obesity in adolescents
Bonita Falkner
Department of Medicine and 
Pediatrics, Thomas Jefferson 
University, Philadelphia, PA, USA
Abstract: Largely due to the childhood obesity epidemic, there has been an increase in the 
prevalence of hypertension in children and adolescents. Obesity associated hypertension is 
the most common hypertension phenotype among adolescents. Approximately 30% of obese 
adolescents have elevated blood pressure (BP) or hypertension. Updated definitions of elevated 
BP and hypertension in adolescents are now similar to definitions of BP status in adults. For 
adolescents ≥13 years of age, elevated BP is 120 to 129/<80 mm Hg. Hypertension, stage 1, is 
≥130 to 139/80 to 89 mm Hg, and hypertension, stage 2, is ≥140/90 mm Hg. BP measurements 
over separate clinic visits are necessary to verify the diagnosis of elevated BP or hypertension. 
Ambulatory BP monitoring, when available, provides confirmatory data on BP status. Causal 
mechanisms for obesity associated hypertension include increased sympathetic nervous system 
activity, increased renal sodium retention secondary to insulin resistance/hyperinsulinemia, and 
obesity mediated inflammation. The primary treatment for obesity associated hypertension is 
weight reduction with lifestyle changes in diet and physical activity. Although difficult to achieve, 
even modest weight reduction can be beneficial. The diet should be rich in fruits, vegetables, 
fiber, and low-fat dairy with reduction in salt intake. When lifestyle changes are insufficient to 
achieve BP control, pharmacologic therapy is indicated to achieve a goal BP of <130/80 mm 
Hg or <90th percentile, whichever is lower. Regular BP monitoring is necessary for ongoing 
management of obesity associated hypertension in adolescents. 
Keywords: adolescents, obesity, blood pressure, hypertension
Introduction
The increase in prevalence of hypertension among youth over the past few decades has 
been well documented. This increase in childhood hypertension prevalence is largely a 
consequence of the childhood obesity epidemic.1–3 Based on current estimates, the overall 
clinical prevalence of hypertension in children and adolescents, based on repeated mea-
surements, is approximately 3.5%, with higher rates among adolescents.4,5 Among obese 
adolescents, the rates are much higher. In a study of blood pressure (BP) and anthropomet-
rics conducted on high school students, the prevalence of elevated BP (prehypertension 
and hypertension combined) was over 30% in obese adolescent boys and between 23% 
to 30%, depending on ethnicity, in obese adolescent girls.4 The greater prevalence of high 
BP among obese adolescents compared to normal weight children has been confirmed in 
several studies on different cohorts and populations.6–8 Obesity is defined as body mass 
index (BMI) ≥95th percentile; and overweight is defined as >85th percentile to <95th 
percentile. In normal weight children and adolescents there is a consistent positive rela-
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tionship of weight with BP throughout childhood growth and 
development. However, excess adiposity disrupts this normal 
relationship. In a cohort of healthy children and adolescents, Tu 
et al.9 demonstrated that the prevalence of elevated BP (≥90th 
percentile) increased by four-fold when BMI exceeded the 85th 
percentile. These findings indicate that in addition to obesity, 
overweight children and adolescents are also at increased risk 
for elevated BP and hypertension.
The aforementioned studies  applied a definition of 
hypertension and prehypertension (elevated BP) based on the 
2004 Fourth Report.10 The recent publication of an update 
of the pediatric clinical practice guidelines (CPG) has modi-
fied the definition of hypertension in adolescents.11 In this 
update, the reference tables on normative childhood BP data 
were revised. Due to the confirmed effect of overweight and 
obesity on an increase in BP throughout childhood, the new 
BP tables are based on BP data only from normal weight 
children and adolescents (BMI <85th percentile). Thus, age, 
sex, and height adjusted BP levels for the 90th percentile, 
designating elevated BP, and 95th percentile, designating 
hypertension, are somewhat lower than the previous norma-
tive BP tables. For children less than 13 years of age, the 
definitions of elevated BP (previously termed “prehyperten-
sion”) and hypertension remain the same. Elevated BP is 
defined as average systolic and/or diastolic BP level that is 
≥90th percentile and <95th percentile; and hypertension is 
defined as average systolic and/or diastolic BP level that is 
≥95th percentile on repeated visits. However, the definition 
for elevated BP and for hypertension among adolescents 
beginning at age 13 years is now different. The new BP 
tables indicate that the 90th percentile for adolescents aged 
13 years and older is close to a systolic BP of 120 mm Hg 
and diastolic BP is <80 mm Hg; and the 95th percentile for 
systolic BP at age 13 years is approximately 130 mm Hg. 
These BP numbers mirror the threshold BP levels that are 
used to define elevated BP and hypertension for adults in 
the new CPG issued by the American College of Cardiology 
and the American Heart Association.12 Therefore, the current 
definition of BP classification and staging for adolescents ≥13 
years of age is as follows: normal BP: <120/<80 mm Hg; 
elevated BP: 120 to 129/<80 mm Hg; hypertension: ≥130/80 
mm Hg. Stage 1 hypertension is 130 to 139/80 to 89 mm Hg; 
stage 2 hypertension is ≥140/90 mm Hg.
These definitions of hypertension and elevated BP in ado-
lescents age 13 years and above are simplified and harmonize 
with the new adult definitions.11 This change should facilitate 
detection of abnormal BP in adolescents. The change should 
also improve recognition of obesity associated hypertension 
in adolescence.
Diagnosis of hypertension in 
adolescents
The diagnosis of hypertension in adolescents require repeated 
BP measurements that are ≥130/80 mm Hg. The average 
of BP measurements in the hypertensive range on three 
separate clinic visits are generally required for diagnosis of 
hypertension in children and adolescents, unless the patient 
is symptomatic. While automated BP measurement devices 
are commonly used in clinical practices, BP measurement by 
auscultation is the preferred measurement method to confirm 
hypertension in children and adolescents. This is because the 
normative BP data and BP tables are based on auscultated 
BP measurements. Over the past decade, a substantial body 
of data and clinical experience have been developed on the 
use of ambulatory BP monitoring (ABPM) in childhood.13 
The updated CPG recommends using ABPM to confirm 
hypertension in adolescents who have repeated elevated BP 
measurements.11 Approximately 25% of children with ele-
vated clinic BP measurements have white coat hypertension, 
a condition in which individuals have hypertension by clinic 
BP measurements but are normotensive on out of office BP 
measurements. When white coat hypertension is confirmed 
by ABPM, further diagnostic testing or treatments to lower 
BP are not indicated. However, periodic BP monitoring is 
recommended. Masked hypertension is a clinical condition 
in which clinic BP measurements are <95th percentile but 
ambulatory BP measurements are ≥95th percentile. Masked 
hypertension has been identified in both children and ado-
lescents.14 Obese adolescents are at greater risk for masked 
hypertension than non-obese adolescents.15 Normally there 
is a BP decrease, or dip, from the awake phase to the sleep 
phase on ABPM. Obese adolescents are also at greater risk 
for abnormal nocturnal dipping, where the decrease in BP 
during the sleep period is <10% of the awake period ABPM.16 
Therefore, ABPM would be useful in evaluating BP status in 
obese adolescents with elevated BP.
Insulin resistance and metabolic 
syndrome
Insulin resistance (the inverse of insulin sensitivity) is 
generally defined as a decrease in insulin mediated glu-
cose uptake in response to physiological (endogenous) or 
exogenous  insulin.17 A biologic consequence of impaired 
insulin mediated glucose uptake is greater insulin secretion, 
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or compensatory hyperinsulinemia, to achieve glucose con-
trol. The resulting chronic hyperinsulinemia leads to other 
potential dysregulatory metabolic and physiologic effects 
including impaired glucose tolerance, and dyslipidemia. 
While insulin resistance is present in many clinical condi-
tions, insulin resistance is the core abnormality underlying 
metabolic syndrome,18 a condition with heightened risk 
for diabetes and cardiovascular disease among adults.19,20 
Because insulin resistance is difficult to quantify clinically, 
the concept of metabolic syndrome provides a strategy to 
identify underlying insulin resistance among individuals 
with multiple cardiovascular/metabolic risk factors. Despite 
some variation in the exact definition of metabolic syndrome, 
the usual definition, from the National Cholesterol Educa-
tion Program Adult Treatment Panel III (ATPIII)21 is three 
of the following five criteria: 1) visceral obesity, based on 
waist circumference, 2) elevated BP, 3) abnormal glucose 
tolerance, 4) elevated plasma triglyceride, and 5) low high 
density lipoprotein (HDL-cholesterol). Using ATPIII criteria 
modified for children, Cook et al.22 examined the prevalence 
of metabolic syndrome in children from the National Health 
and Nutrition Examination Survey (NHANES) data periods 
1988–1994. Modifications of criteria for children included 
BP ≥90th percentile, waist circumference >95th percentile 
or BMI ≥95th percentile, and triglyceride level ≥95th per-
centile on childhood reference table. In this study, metabolic 
syndrome was identified in 4.2% of children aged 5 to 18 
years. However, among obese adolescents, the prevalence 
was as high as 28.7%. Another study on a cohort of obese 
children and adolescents found elevated BP (≥90th percen-
tile), confirmed by repeated BP measurement, in 37% of the 
cohort. More boys with elevated BP had low HDL-cholesterol 
compared to boys with normal BP.23 Weiss et al.24 reported 
that the prevalence of metabolic syndrome increased with the 
severity of obesity and reached 50% among severely obese 
youth. Obesity is strongly associated with insulin resistance, 
which is manifest by relative hyperinsulinemia.25 Obesity and 
elevated BP are two criteria of metabolic syndrome. It is also 
evident that other components of metabolic syndrome are 
frequently identified among obese adolescents who express 
the phenotype of obesity with elevated BP. Therefore, it can 
be clinically useful to screen obese adolescents with elevated 
BP for plasma lipids and glucose levels.
Mechanisms for obesity associated 
hypertension 
Various theories have been proposed to explain a causal role 
for obesity in elevated BP or hypertension. One theory is that 
hyperinsulinemia, as a consequence of insulin resistance, 
activates the sympathetic nervous system (SNS).26 A poten-
tial mechanism for SNS activation could be adipose tissue 
production of leptin, which is commonly elevated in obese 
individuals.27,28 Further support for heightened SNS activity 
in obese hypertensive adolescents was developed using data 
from 24 hour ABPM. Compared to normal weight hyperten-
sive adolescents, obese hypertensive adolescents have higher 
heart rates and greater variability during ABPM, suggesting a 
hyperkinetic hemodynamic condition.8,29,30 While heightened 
SNS activity is likely present among obese adolescents, it is 
not the only pathway involved in the association of obesity 
with elevated BP.
Dietary sodium has been implicated in the association of 
excess adiposity and elevated BP in children and adolescents. 
Rosner et al.3 examined childhood BP trends from sequential 
NHANES data periods 1988 to 2008. These investigators 
demonstrated a progressive increase in both the BP level 
and in the prevalence of high BP in children and adolescents. 
In their analyses the predictors of increasing BP level and 
prevalence of high BP were higher BMI and waist circumfer-
ence, and greater dietary sodium intake. In another study on 
NHANES data Yang et al.31 examined sodium intake on 6,000 
children and adolescents, of whom 37% were overweight 
or obese. The overall average sodium intake was 3.387 mg/
day. The cohort was then stratified according to quartiles of 
sodium intake, and within each quartile participants were 
grouped as normal weight or overweight/obese. For the 
entire cohort, the odds ratio (OR) for risk of elevated BP/
hypertension in the highest sodium quartile compared to the 
lowest quartile was 2.0. However, among the overweight/
obese participants, the adjusted OR for risk of elevated BP/
hypertension in the highest sodium quartile increased to 3.5; 
P = 0.013. Results of these recent epidemiologic studies 
indicate that obese children and adolescents have greater 
BP sensitivity to sodium intake compared to normal weight 
children and adolescents.
The relative hyperinsulinemia associated with obesity 
in children, as well as adults, can contribute to greater BP 
sensitivity to sodium intake. Both clinical and experimental 
research demonstrate that insulin upregulates renal tubular 
sodium transport. Higher circulating plasma insulin levels 
can augment sodium reabsorption in the distal tubules which 
would increase BP. This concept is in line with the results of 
a study by Rocchini et al.32 on a sample of obese adolescents 
with elevated BP. BP was measured in the obese adolescents 
following 2 weeks on a high salt diet; and BP measurements 
were obtained again following 2 weeks on a low salt diet. 
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There was a significant reduction in BP following the low 
salt diet indicating BP sensitivity to sodium. A weight reduc-
tion intervention was then provided for the obese adolescent 
participants over several weeks. Following weight reduction 
efforts, the high and low salt procedures were repeated. 
Among the obese adolescents without any weight reduc-
tion, the BP response from high to low salt procedures were 
unchanged. Whereas, among obese adolescents who achieved 
modest weight reduction, there was a reduction in the BP 
change from high to low salt diet supporting the concept that a 
decrease in adiposity resulted in a reduction in BP sensitivity 
to sodium. Despite limitations in the literature on the role of 
dietary salt and BP in youth, the available evidence support 
a contribution of high sodium intake on increases BP among 
children and adolescents who are overweight or obese.
Another theory to explain the obesity-hypertension 
association in both adolescents and adults is alterations 
in microvascular function and structure mediated through 
inflammation. Obesity is associated with elevated levels of 
pro-inflammatory cytokines, including C-reactive protein 
(CRP) and interleukin-6 (IL-6).33 Similar elevations of 
these cytokines have been reported in obese adolescents.24,34 
Obesity is associated with an accumulation of macrophages 
in adipose tissue, which may contribute to obesity-related 
inflammation.35 Support for a causal role of inflammation in 
development of hypertension is largely based on experimen-
tal studies that focus on endothelial dysfunction.36,37 When 
human vascular endothelial cells are exposed to CRP in vitro, 
there is a resulting decrease in expression of endothelial nitric 
oxide synthase with subsequent attenuation of vasodilation 
responses.38 Experimental works have investigated a role of 
perivascular adipose tissue (PVAT) in the signaling of inflam-
matory cytokines. Excess PVAT contributes to endothelial 
dysfunction and increases vascular smooth muscle tone.39,40 
This concept was investigated by Greenstein et al.41 who used 
PVAT from lean and obese humans. In in vitro experiments, 
the investigators found that, compared to PVAT from lean 
individuals, vasodilatory capacity was lost in PVAT from 
obese subjects; and in the obese tissues there was concurrent 
expression of mediators of inflammation and oxidative stress. 
It is plausible that microvascular dysfunction, mediated 
by PVAT-derived inflammation could contribute to insulin 
resistance and capillary rarefaction, both of which create a 
platform for increased vascular resistance and hypertension. 
The potential causal mechanisms underlying obesity asso-
ciated hypertension among adolescents are likely overlapping 
with possible synergistic action. Despite gaps in complete 
understanding of fundamental mechanisms, it is clear that 
obesity is associated with insulin resistance with compensa-
tory hyperinsulinism; and that in adolescence, this condition 
has many adverse consequences including elevated BP and 
premature adult onset cardiovascular disease.
Management of adolescents with 
obesity and elevated BP
Management of adolescents with elevated BP or suspected 
hypertension include confirming the BP status, evaluation 
for other obesity-related risk factors, and interventions to 
achieve a more optimal BP. For elevated BP (120/<80 to 
129/<80 mm Hg) or hypertension (≥130/80 mm Hg) mea-
sured during a clinical visit, repeated BP measurements are 
needed at the time of the visit or on subsequent visits when 
the patient is without symptoms. Repeat BP measurements 
by auscultation are preferred.11 Usually, three separate visits 
for accurate BP ascertainment are needed to confirm that 
the average BP is normal, elevated, or hypertensive. Due to 
the known prevalence of white coat hypertension, ABPM is 
now recommended to confirm the BP status. ABPM is also 
informative for obese adolescents who have greater risk 
for masked hypertension.15 For adolescents with confirmed 
elevated BP or hypertension, additional screening for obesity-
related risk factors including plasma lipids and glucose can be 
informative of overall health status. Detection of dyslipidemia 
or impaired glucose tolerance would indicate metabolic syn-
drome which serves to intensify efforts on weight reduction. 
A sleep history is useful, especially in very obese adolescents, 
as sleep disordered breathing or obstructive sleep apnea is 
often associated with hypertension in adolescents.11 Further 
diagnostic studies are generally not necessary during the 
initial evaluation unless the patient has a history of previous 
renal disorders, or a family history of chronic kidney disease. 
The major intervention in management of hypertension in 
obese adolescents is weight reduction. Unfortunately, weight 
reduction is also very difficult to achieve for obese adoles-
cents, as well as for obese adults. Lifestyle interventions that 
include changes in diet and increasing physical activity are 
key for weight reduction and, when achieved over a period 
of time, have been shown to lower BP in children and ado-
lescents.42,43 For stage 1 hypertension, lifestyle interventions 
with BP monitoring should be tried for 6 to 12 months.11 
The dietary approach to stop hypertension (DASH) 
diet plan has demonstrated impressive reductions in BP in 
adults.44,45 The DASH diet includes high intake of fruits, 
vegetables, whole grains, and low-fat dairy along with 
reductions in sodium intake. A small clinical trial tested the 
DASH diet versus routine nutritional counseling (RC) in a 
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sample of hypertensive adolescents. Following 3 months on 
the diets there was significantly greater BP reduction in the 
DASH diet group compared to the RC group; and this change 
persisted for 6 months.46 The DASH diet is an appropriate 
style diet to recommend for obese adolescents. Reductions 
in dietary sodium intake should be incorporated into the 
DASH diet plan, especially because average sodium intake of 
adolescents is well above recommended levels of 2,500 mg/
day. To achieve a reduction in sodium intake it is necessary 
to limit processed, prepared, and “fast” foods; which are food 
items generally preferred by adolescents.
Physical activity is beneficial in weight reduction efforts 
and also improves cardiovascular fitness. Any type of exercise 
is beneficial and can include aerobic training, resistance train-
ing or combined training.47 Moderate to vigorous physical 
activity should be encouraged, with a goal of 30 to 60 minutes 
on at least 5 days a week. For obese adolescents, the increase 
in physical activity needs to be gradual to avoid injury, and 
should include activities that are pleasant and sustainable. 
While most obese adolescents are not competitive athletes, 
they should not be restricted from participating in organized 
sports programs. However, it is recommended that athletic 
participation by adolescents who have stage 2 hypertension 
have their participation in high-static competitive sports 
restricted until their BP is controlled with lifestyle modifica-
tion and/or pharmacologic therapy.48 
Pharmacologic therapy to lower BP is indicated for 
hypertensive adolescents when there is insufficient or no 
response to lifestyle interventions. Drug treatment is also 
indicated for adolescents with symptomatic hypertension or 
persistent stage 2 hypertension. Therefore, pharmacologic 
therapy should be considered earlier than 6 months of lifestyle 
interventions in obese adolescents with stage 2 hypertension. 
With stage 2 hypertension, pharmacologic treatment can be 
considered following 1 to 3 months of lifestyle interventions, 
but lifestyle interventions should continue in conjunction 
with drug treatment. Prior to beginning antihypertension 
medications an echocardiogram should be obtained for 
assessment of possible target organ damage. A finding of 
left ventricular hypertrophy (LVH) on echocardiogram is 
evidence of hypertensive mediated target organ damage and 
warrants further effort to lower BP.11 It should be noted that 
obesity also contributes to LVH, an effect that is independent 
of BP.49,50 Therefore, both high BP and obesity contribute to 
LVH, and BP reduction alone may be insufficient to reduce 
LVH. It is also prudent to consider if there could be an under-
lying secondary cause of the hypertension, in addition to the 
obesity. Standard screening would be a renal ultrasound and 
blood studies including a complete blood count, electrolytes, 
creatinine, renin, and aldosterone. 
Recommendations on antihypertensive drug therapy in 
children and adolescents were updated in the recent CPG.11 
Drug treatment should begin with a single agent at the low 
end of the dosing range. For initial treatment, the preferred 
choices are angiotensin converting enzyme (ACE-inhibitor), 
angiotensin receptor blocking (ARB) agent, long-acting cal-
cium channel blocker (CCB), or a thiazide diuretic. The dose 
can be up-titrated every 2 to 4 weeks, with BP monitoring 
every 4 to 6 weeks until the BP is normalized (<130/<80 mm 
Hg or <90th percentile, whichever is lower on the new BP 
tables).11 If BP response is insufficient at maximum dose of a 
single agent, a second drug can be added. A thiazide diuretic 
is generally the preferred second drug choice. For African 
American adolescents, who may not have a brisk response to 
ACE-inhibitors, the initial dose could be somewhat higher. 
If LVH is present, ACE-inhibitors or ARBs are initial drug 
choice. However, ACE-inhibitors and ARBs can have tera-
togenic effects on fetal development and are contraindicated 
in pregnancy. Adolescent girls with childbearing potential 
should be counseled on the possible risks of these drugs, 
and if there is a risk of pregnancy an alternative drug, such 
as a CCB, should be prescribed. Beta-blocking agents are 
generally not recommended as initial drug choices in obese 
adolescents, because many of these drugs have an adverse 
effect on insulin resistance. If the BP control is not achieved 
with three drugs, non-compliance should be considered or 
possibly a missed diagnosis of secondary hypertension. 
Repeat BP monitoring with ABPM can be useful in these 
situations. While drug therapy may be necessary to achieve 
BP control, efforts to reduce excess body weight with lifestyle 
changes should be continued. If weight loss is achieved, it 
may become possible to decrease or even withdraw drug 
therapy. However, even with withdrawal of drug treatment, 
regular BP monitoring should continue.
Summary
Hypertension associated with obesity is commonly found in 
adolescents. Approximately 30% of adolescents with obesity 
have elevated BP or hypertension. Overweight and obese ado-
lescents have greater BP sensitivity to dietary salt compared 
to normal weight adolescents. The relative endogenous hyper-
insulinemia associated with obesity contributes to the salt 
sensitivity. While there are other possible mechanisms that 
contribute to elevated BP/hypertension in obese adolescents, 
the optimal treatment is weight reduction. Although achiev-
ing a normal body weight is extremely difficult, even modest 
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reductions in weight can be beneficial. Dietary changes with 
a shift from processed high salt foods to a diet rich in fruits, 
vegetables, fiber, and low fat dairy along with a reduction 
in sodium intake are important initial therapy along with 
an increase in physical activity. If BP reduction by lifestyle 
change is not achieved, drug therapy can be beneficial in 
achieving control of BP. Initial BP monitoring, including 
ABPM is necessary to confirm hypertension status. And 
when BP control is achieved, BP monitoring should continue 
to ensure that BP control continues through adolescence. 
Disclosure
The author reports no conflicts of interest in this work. 
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